June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Association between heavy metals and diabetic retinopathy in the National Health and Nutrition Examination Surveys (NHANES)
Author Affiliations & Notes
  • Anne Xuan-Lan Nguyen
    Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada
  • Leonardo Landó
    Ophthalmology, University of Toronto, Toronto, Ontario, Canada
  • Xuan-Vi Trinh
    Computer Science, McGill University, Montreal, Quebec, Canada
  • Jerry Kurian
    None, Montreal, Quebec, Canada
  • Vincent Quoc-Huy Trinh
    Pathology, Vanderbilt University, Nashville, Tennessee, United States
  • Albert Y. Wu
    Ophthalmology, Stanford University, California, United States
  • Footnotes
    Commercial Relationships   Anne Xuan-Lan Nguyen None; Leonardo Landó None; Xuan-Vi Trinh None; Jerry Kurian None; Vincent Trinh None; Albert Wu None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 556 – A0121. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anne Xuan-Lan Nguyen, Leonardo Landó, Xuan-Vi Trinh, Jerry Kurian, Vincent Quoc-Huy Trinh, Albert Y. Wu; Association between heavy metals and diabetic retinopathy in the National Health and Nutrition Examination Surveys (NHANES). Invest. Ophthalmol. Vis. Sci. 2022;63(7):556 – A0121.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : While studies have suggested relationships between neurotoxic heavy metals (HM) and diabetes (DB), they did not correlate such findings with complications like diabetic retinopathy (DR). We performed a retrospective, observational cohort study to assess the relationship between HM and DR.

Methods : We extracted all patient data from CDC’s NHANES with DB and ophthalmic parameters, corresponding to NHANES 2005/6 and 2007/8 cycles. We recorded socio-demographic factors, DB-related factors, HM measures and DR severity. To correct for cycle variations in testing, HM levels were transformed into cycle-specific quartiles. We performed statistical tests (Mann-Whitney U, Pearson Chi2, Spearman’s Rho Coefficient (p), Welch’s T-test, multivariable logistic regression), in SPSS, v26. Outcome measures included: serum and urine levels of HMs compared to the degree of DR, past medical history and social history.

Results : 884 eligible patients were classified into 4 groups based on their DR severity: no DR (n=565, 46.5% men), mild DR (n=203, 56.7% men), moderate DR (n=85, 56.3% men), and proliferative DR (n=31, 35.5% men). The average age in each group was respectively 63.1±10.6, 65.1±11.0, 61.4±10.2 and 63.4±7.4 years. Mean serum HM levels for lead, cadmium, total mercury and inorganic mercury did not differ significantly in the presence or absence of DR (p>0.05, Welch’s t-tests). All mean urinary metal levels were not significantly different in the presence or absence of DR, except for thallium (UThal) which had significant lower levels in DR (p<0.013). Adjustments for cycle variations confirm the independent association of DR and UThal, and the absence of correlation with other blood and urinary HM levels (Figure 1). UThal was the most significant correlation with a Spearman p of -0.214 (p=0.0003). We then analyzed the population to see which other parameter was associated with UThal levels. UThal was significantly associated with eGFR (p=0.002), hemoglobin (p=0.040), and insulin therapy (p=0.010). Multivariate logistic regression with 3 models are presented in Table 1. UThal was still independently associated with DR in all models (p=0.011-0.042).

Conclusions : UThal is significantly associated to DR severity in the NHANES database. Additional validation for geographic factors are warranted. If validated, these findings suggest a possible role for thallium, a neurotoxic HM, in DR.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×